It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Spending on older medicines like metformin, used only for diabetes, declined. But that of popular GLP-1 drugs such as Novo ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...

Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.